FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin
On Thursday, Reuters reported that the U.S. Food and Drug Administration is ending the Commissioner’s National Priority Voucher, pulling back from a program created by President Trump as part of his April Executive Order. The vouchers were intended to expedite the review period for drugs that align with national health priorities, such as addressing unmet medical needs. Under the program the drug review process that usually takes 10-12 months was compressed down to 1-2 months.
Three psychedelics-related drug makers were given vouchers and are now far along in the FDA review pipeline. Ending the program puts the timeline for approval into question for UK-based Compass Pathways’ COMP360, a proprietary synthetic psilocybin formulation studied for treatment-resistant depression, as well as the Wisconsin-based non-profit Usona Institute’s psilocybin for major depressive disorder, and New York-based Transcend Therapeutics’s methylone, which is similar to MDMA, for PTSD. The Microdose reached out to all three companies for comment but did not get a response before publication.
“Once touted as a bold fix for US pharmaceutical regulation, the program has been left adrift, offering a stark window into the internal chaos, infighting, and lack of steady leadership that have plagued the FDA, which has been without a commissioner since May,” writes Reuters. Twenty-two drug makers were given a voucher and of those, a dozen have already been approved, according to Reuters. The Department of Health and Human Services has not confirmed the end of the voucher program. Sources told Reuters that drugs already in the program but not yet approved will be turned over to FDA’s career scientists for review.
On Monday, Compass announced that it submitted final materials for COMP360’s New Drug Application to the FDA. The news comes a week after Psychedelic Alpha reported that competitor Usona submitted its New Drug Application for PSIL201, its psilocybin candidate for major depressive disorder. Many in the field were predicting that under the expedited voucher program, COMP360 and Usona’s psilocybin could have been approved before the end of the year. Now that timeline is up in the air; just how these changes will affect drug makers is not yet clear.